1152475-42-7

Basic information

• Product Name: 7-Bromo-2-chlorothieno[3,2-d]pyrimidine
• Synonyms: 7-Bromo-2-chlorothieno[3,2-d]pyrimidine
• CAS NO: 1152475-42-7
• Molecular Formula: C₆H₂BrClN₂S
• Molecular Weight: 249.51548
• Product Categories: Heterocycle-Pyrimidine series
• Mol File: 1152475-42-7.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Density: 1.955
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: -0.83±0.40(Predicted)
• CAS DataBase Reference: 7-Bromo-2-chlorothieno[3,2-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Bromo-2-chlorothieno[3,2-d]pyrimidine(1152475-42-7)
• EPA Substance Registry System: 7-Bromo-2-chlorothieno[3,2-d]pyrimidine(1152475-42-7)

Safety Data

• Hazardous Substances Data: 1152475-42-7(Hazardous Substances Data)

Usage

General Description

7-Bromo-2-chlorothieno[3,2-d]pyrimidine is a chemical compound with the molecular formula C6H3BrClN2S. It is a heterocyclic compound consisting of a thieno and pyrimidine ring with bromine and chlorine substituents. 7-Bromo-2-chlorothieno[3,2-d]pyrimidine is primarily used in pharmaceutical and agrochemical applications as a building block for the synthesis of various biologically active molecules. It is also used in research and development of new drugs and materials. The chemical properties and structure of 7-Bromo-2-chlorothieno[3,2-d]pyrimidine make it a versatile and valuable compound in the field of organic synthesis.

Upstream product

• 1119280-68-0 2-chlorothieno[3,2-d]pyrimidine 
• 16234-14-3 2,4-dichlorothieno[3,2-d]pyrimidine 
• 1293987-55-9 7-bromo-2-chloro-3,4-dihydrothieno[3,2-d]pyrimidine 
• 22288-78-4 Methyl 3-aminothiophene-2-carboxylate 
• 41102-25-4 7-bromo-2,4-dichloroimidazo[2,1-f][1,2,4]triazine 
• 41102-02-7 7-bromothieno[3,2-d]pyrimidine-2,4(1H,3H)-dione 
• 16233-51-5 1H-thieno[3,2-d]pyrimidine-2,4-dione 

Downstream Products

• 1152475-66-5 2-chloro-7-phenylthieno[3,2-d]pyrimidine 
• 1152474-52-6 7-bromo-N-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)thieno[3,2-d]pyrimidin-2-amine 
• 1293987-56-0 3-(2-chlorothieno[3,2-d]pyrimidin-7-yl)benzenamine 
• 1293987-77-5 2-chloro-N-(3,4,5-trimethoxyphenyl)thieno[3,2-d]pyrimidin-7-amine 
• 1293987-76-4 N-(3-(2-chlorothieno[3,2-d]pyrimidin-7-yl)phenyl)-N-methylmethanesulfonamide 
• 1293987-54-8 N-(3-(2-(6-(4-ethylpiperazin-1-yl)pyridin-3-ylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)methanesulfonamide hydrochloride 
• 1293987-57-1 N-(3-(2-chlorothieno[3,2-d]pyrimidin-7-yl)phenyl)-methanesulfonamide 
• 1293987-05-9 N-(3-(2-(6-(4-ethylpiperazin-1-yl)pyridin-3-ylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)methanesulfonamide 
• 1313036-45-1 N-(2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)-7-(3-nitrophenyl)thieno[3,2-d]pyrimidin-2-amine 
• 1313036-46-2 7-(3-aminophenyl)-N-(2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)thieno[3,2-d]pyrimidin-2-amine 
• 1313036-25-7 N-(3-(2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)thieno[3,2-d]pyrimidin-7-yl)phenyl)acrylamide 

Relevant articles and documents

Identification of Thieno[3,2- d]pyrimidine Derivatives as Dual Inhibitors of Focal Adhesion Kinase and FMS-like Tyrosine Kinase 3

Focal adhesion kinase (FAK) is overexpressed in highly invasive and metastatic cancers. To identify novel FAK inhibitors, we designed and synthesized various thieno[3,2-d]pyrimidine derivatives. An intensive structure-activity relationship (SAR) study led

FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF

Disclosed area fused ring pyrimidine compound, and an intermediate, a preparation method, a composition and a use thereof. The fused ring pyrimidine compound is a compound as shown in formula I, a tautomer, an enantiomer, a diastereoisomer, a pharmaceutically acceptable salt, a metabolite, a metabolic precursor or a prodrug thereof, wherein the above-mentioned compound is used for the preparation of a medicine for preventing, remitting or treating one or more of immune system diseases, autoimmune diseases, cell proliferative diseases, allergic disorders and cardiovascular diseases, and the compound has a strong inhibitory effect on the Janues kinase, FGFR kinase, FLT3 kinase and Src family kinase.

COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH

Provided are compounds and methods for treating or preventing kinase-mediated disorders therewith.